November 2021 ERCC webinar from Michael Segel

The November 2021 ERCC webinar is from Michael Segel.

This blog originated as a press release from the Max Planck Institute for Medical Research in Heidelberg. Thanks to them for allowing us to repost it here.

Scientists create synthetic exosomes with natural functionalities and present their therapeutic application.

Scientists from the Max Planck Institute for Medical Research in Heidelberg and colleagues at the DWI Leibniz Institute for Interactive Materials in Aachen have engineered synthetic exosomes that regulate cellular signaling during wound closure. The synthetic structures are built to resemble naturally occurring extracellular vesicles (EV) that play a fundamental role in communication between cells during various processes in our bodies. The scientists uncovered key mechanisms in the regulation of wound healing and the formation of new blood vessels. They designed and built programmable fully-synthetic EVs from scratch rather than isolating natural EVs from cells. Inspired by the roles of the natural counterparts, the scientists demonstrate for the first time that fully synthetic exosomes with therapeutic functions can be constructed.

Continue reading

This blog originated as a press release from the Technical University of Denmark (DTU). Thanks to them for allowing us to repost it here.

DTU Health Tech researchers have developed a method for detection of SARS-CoV-2 RNA that can be adapted to detect other diseases.

Current SARS-CoV-2 RNA detection methods recommended by the World Health Organization profoundly rely on the roles of biological enzymes. High cost, stringent transportation and storage conditions, as well as a global supply shortage of enzymes, limit large-scale testing. The result is that most countries have to prioritize testing on vulnerable cases, which creates delay in diagnostics and identification of positive cases, which again can hamper pandemic mitigation and suppression.

Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) is still the gold standard for whole genome detection and has been playing a key role in controlling the COVID-19 pandemic. However, the sample-to-result time for qRT-PCR is several hours, and the method requires a complex thermocycler instrument to raise and lower the temperature of the reaction in discrete steps.

Simpler and less expensive

Non-enzymatic isothermal amplification methods, being simpler and faster, have shown promising potential to substitute for qRT-PCR. Although these methods perform very well when the target gene is short, they are yet to function efficiently for detection of whole viral genomes (long DNA or RNA targets).

During the COVID-19 pandemic, the Euro area alone experienced a 3.8% drop in GDP within the first quarter of 2020 (Eurostat 2020). Thus, developing a lower-cost methodology for pathogen detection would be highly beneficial for both patients and the healthcare systems aiming to battle future pandemics.

Associate Professor Yi Sun and Postdoc researcher Mohsen Mohammadniaei at DTU Health Tech have invented a one-pot assay, which they have named NISDA (Non-enzymatic Isothermal Strand Displacement and Amplification assay). The assay is for rapid detection of SARS-CoV-2 RNA without the need for the RNA reverse transcription step of the qRT-PCR methodology. Being one-pot enables a single step detection routine. The user only needs to add the sample into a single tube, place it in the instrument, and wait for 30 minutes to obtain the result.

The assay works at constant temperature, requires no enzymes, and is based on the toehold-mediated strand displacement (TMSD) approach. TMSD is an enzyme-free molecular tool from which one strand of DNA or RNA (output) is displaced by another strand (input) to form a more stable duplex structure.

High accuracy and sensitivity

The NISDA assay was able to detect a very low concentration of RNA (10 copies/µL) in only 30 minutes. In collaboration with Hvidovre Hospital and Bispebjerg Hospital, the research team clinically validated the NISDA assay, acheiving 100% specificity as well as 96.77% and 100% sensitivity when setting up in the laboratory and hospital, respectively.

Associate Professor Yi Sun elaborates, “We exploited the TMSD approach and designed three DNA probes. One probe exchanged the whole genome to a short DNA strand and the other two probes utilized the exchanged short DNA for triggering a fluorescence signal amplification cascade reaction. The beauty of NISDA assay is its simplicity. We removed the usage of enzymes to reduce the assay cost and enhance its robustness at room temperature.”

In the assay workflow, the extracted RNA from throat swab samples is added to the reaction mixture and incubated at 42°C for 30 minutes. The next step is fluorescence measurement, and samples with significantly higher fluorescence signals than that of the control samples are considered positive.

Schematic of NISDA assayThe NISDA assay comprises a single tube containing three DNA probes. After the addition of the extracted RNA from swab samples and incubation at 42°C for 30 min, positive samples show higher fluorescent signals than negative samples.

Towards a multiple disease diagnostics tool

“Being directly involved in improving people’s health is the ultimate dream of a biomedical researcher and we believe that the NISDA assay has given us this wonderful chance to attain that ambition”, Postdoctoral Researcher Mohsen Mohammadniaei says.

“The next step is to further design the NISDA assay for detecting different pathogens and develop a point-of-care diagnostic device for multiple disease diagnostics. Another advantage of the NISDA assay is its ability to be designed for short RNA targets such as cancer biomarker microRNA. We are currently exploring different schemes for the commercialization of the NISDA assay and we are certain that the NISDA assay will become widely-known in the near future”, Associate Professor Yi Sun finishes.

Reference

Mohammadniaei M et al., A non-enzymatic, isothermal strand displacement and amplification assay for rapid detection of SARS-CoV-2 RNA. (2021) Nat Comm 12: 5089. doi: 10.1038/s41467-021-25387-9 PMID: 34429424.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has announced a new funding opportunity for characterization of islet-derived extracellular vesicles (EVs) for improved detection, monitoring, classification, and treatment of Type 1 Diabetes (T1D).

This initiative will support the development of tools and experimental platforms for the purification and characterization of EVs originating from the human pancreatic islet and its broader tissue environment in healthy individuals, and individuals with T1D or at-risk of developing the disease. It will also support the exploration of the contribution of pancreatic EV biology to islet function, dysfunction and T1D disease initiation; the development of EV-based diagnostic tools for disease monitoring and classification; and the use of pancreatic EV biology to identify novel therapeutic targets.

A letter of intent to apply for the grant must be sent by October 3, 2021.

For more information, see https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-016.html.

Keep up with developments in the field of exRNA research!

Sign up for periodic updates from the ERCC, including announcements about our monthly webinar series.